Patent ID: 9249159
Filing Date: 2016-02-02
CPC Classification: A61K,C07D

Claim Text:
1. A method for treating hepatitis C virus in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a PRK2 (Protein Kinase C-related Kinase 2) inhibitor, wherein the PRK2 inhibitor is selected from the group consisting of: 3-[(2-ethylbutanoyl)amino-N-(pyridine-4-yl)benzamide], cyclohexanecarboxylic acid (1H -benzoimidazole-5-yl)-amide, (3r, 5r, 7r)-N-(quinolin-5-yl)adamantane-1-carboxamide, 1-methyl-4-phenylpiperidine-4-carbonitrile), N-(2-oxoazepan-3-yl)pyridine-4-carboxamide), 2-oxo-N-4-pyridinyl-3-piperidinecarboxamide, N-(2-oxoazepan-3-yl)pyridine-4-carboxamide, 2-oxo-N-(pyridine-4-yl)-2H-chromene-3-carboxamide, 2-oxo-N-(4-pyridinyl)-1,2-dihydro-3-pyridinecarboxamide, 1-benzyl-2-oxo-N-(4-pyridinyl)-1,2-dihydro-3-pyridinecarboxamide, and 5-oxo-N-pyridine-4-yl-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide.